AbbVie (ABBV)
The desk's stance
On our research list, not on the slate.
What the company does
The patent-cliff masterclass: absorbed Humira generic erosion as Skyrizi and Rinvoq surged double-digits past peak Humira sales, proving that a dominant immunology portfolio can out-execute a $20B cliff.
In short: Immunology and neuroscience biopharma. Category: Large-Cap Biopharma Value. Sector: Healthcare, Drug Manufacturers - General.
G-Street Value and Score
G-Street Value: $276.83, computed Oct 18, 2026 (confidence: high).
How we got there: 70% analyst leg $276.83 (5 analyst targets, credibility- and freshness-weighted, after 8% optimism discount) + 30% GainStreet factor value $277.96 (17.14× fwd EPS anchored to healthcare multiples) — capped at the analyst leg; factors never out-bull the street.
G-Street Score: 59 out of 100 (Weak).
- Top-line growth & guidance: 10 of 32
- Margin power: 15 of 15
- Revenue visibility & quality: 5 of 11
- Profitability & balance sheet: 19 of 24
- Capital allocation & governance: 5 of 6
- Valuation, sentiment & momentum: 5 of 12
Our current thesis
Updated Oct 18, 2026
The thesis
- Skyrizi and Rinvoq volume growth decisively overcomes Humira patent cliff, sustaining double-digit top-line momentum.
- Robust neuroscience and oncology pipelines offer commercial durability extending deep into the 2030s.
- Trailing free cash flow of $18.2B comfortably supports dividends and debt service obligations.
Risks
- Heavy $70.9B debt burden and recurring acquisition charges suppress reported GAAP profitability.
- Trading near 52-week highs above consensus target leaves virtually zero margin of safety.
- Execution hiccup in Q1 EPS miss highlights margin vulnerability to milestone and IPR&D costs.
What we're watching
- Q3 2026 earnings on October 30 focusing on Skyrizi run-rate and fiscal year guidance.
- Phase 3 clinical progress and regulatory updates for epcoritamab and telisotuzumab adizutecan.
- Technical price behavior around the $291.40 52-week high resistance level.
Latest
AbbVie trades at $285.42, hovering just below its 52-week high of $291.40 after Q2 revenue rebounded 10.2% YoY to $16.99B on resilient Skyrizi and Rinvoq demand. Ahead of Q3 earnings on October 30, consensus models $17.35B in net revenue, though recent IPR&D charges led management to trim full-year adjusted EPS guidance to $13.76–$13.96. At 17.6x forward earnings and an elevated $70.9B debt load, valuation fully reflects the post-Humira growth recovery relative to sell-side targets.
Key numbers
As of Oct 16, 2026: market cap $504.4B · revenue growth +10.2% year over year · gross margin 72.8% · net margin 9.8% · forward P/E 17.6 · next earnings Oct 30, 2026.
Analyst price targets
Published analyst targets we could trace to a named source.
- Morgan Stanley, Overweight: $310 target (October 2026). Source: www.tipranks.com
- Bank of America, Buy: $305 target (October 2026). Source: www.tipranks.com
- JPMorgan, Overweight: $300 target (October 2026). Source: www.marketbeat.com
- Cantor Fitzgerald, Overweight: $290 target (October 2026). Source: marketbeat.com
- Wells Fargo, Overweight: $300 target (August 2026). Source: www.investing.com
On the Gainz Lab maps
Who it does business with
- AbbVie competes with Johnson & Johnson — Immunology turf. Skyrizi and Rinvoq vs Tremfya and Darzalex across psoriasis, arthritis, and IBD — the highest-grossing non-obesity turf war in pharma.